<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03450915</url>
  </required_header>
  <id_info>
    <org_study_id>BVX-010</org_study_id>
    <nct_id>NCT03450915</nct_id>
  </id_info>
  <brief_title>A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine</brief_title>
  <official_title>A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BiondVax Pharmaceuticals ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BiondVax Pharmaceuticals ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged&#xD;
      50+ over two years. Participants will be immunized twice with the M-001 universal influenza&#xD;
      vaccine candidate or placebo and then followed for up to 2 seasons. The trial will evaluate&#xD;
      the number of influenza cases in each group and the severity of illness during the follow up&#xD;
      period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The placebo-controlled pivotal clinical efficacy Phase 3 trial plans to enroll a total of&#xD;
      approximately 12,460 participants over two years. Participants will be immunized twice with&#xD;
      the M-001 influenza vaccine candidate or placebo. Influenza incidence and illness severity&#xD;
      will be evaluated throughout the follow-up period of up to two years. Participants will be 50&#xD;
      years and older, with at least half over 65 years of age.&#xD;
&#xD;
      The trial is expected to take place in eastern European countries and begin prior to the&#xD;
      2018/19 Northern Hemisphere flu season.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">October 23, 2020</completion_date>
  <primary_completion_date type="Actual">July 2, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental group: 2 immunizations with M-001 Control group: 2 injection of saline (placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All parties are blinded except for the person who prepares the syringe for injection. The M-001 is cloudy white and its appearance is different from the transparent saline that is used for placebo. The person prepares the syringe with an opaque sticker that fully covers the syringe contents. People administering the syringe are not involved or present during syringe preparation, and are thus fully blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With qRT-PCR or Culture-confirmed Influenza-like Illness</measure>
    <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
    <description>Prevention of influenza disease by comparing the occurrence of either qRT-PCR or culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Events, New Onset Chronic Illness, and Non-solicited Adverse Events</measure>
    <time_frame>From Day 0 to end of study completion by participant which coincides with end of flu season in the respective year, an average of 4 months per participant per year</time_frame>
    <description>Number of participants with one or more Serious Adverse Events, New Onset Chronic illness, and Non-solicited Adverse Events assessed during one flu season per participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Culture-confirmed Influenza Incidence</measure>
    <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
    <description>Occurrence of culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Reduction of Severity of qRT-PCR or Culture-confirmed Influenza</measure>
    <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
    <description>Assessed by reduction of severity of either qRT-PCR or culture-confirmed influenza illness by the reduction due to M-001 in the average number of days with respiratory or systemic symptoms during the first laboratory-confirmed influenza illness episode.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Influenza-like Illness Symptoms</measure>
    <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
    <description>Assessment of number of participants having ILI symptoms in the experimental or control group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12460</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>M-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-001</intervention_name>
    <description>A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
    <arm_group_label>M-001</arm_group_label>
    <other_name>Multimeric-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.9% sodium chloride (NaCl)</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects 50 years of age (inclusive) or older, mentally competent,&#xD;
             willing and able to give the written informed consent prior to study entry&#xD;
&#xD;
          2. Able to comply with the trial procedures and be available for all study visits.&#xD;
&#xD;
          3. Medically stable. (Subjects may have underlying chronic conditions such as&#xD;
             hypertension, diabetes, ischemic heart disease, or hypothyroidism, as long as their&#xD;
             symptoms/signs are controlled. If they are on medication for a condition, the&#xD;
             medication dose must have been stable for at least 3 months preceding vaccination).&#xD;
&#xD;
          4. Women of childbearing potential (not surgically sterile or postmenopausal for greater&#xD;
             than or equal to one year) and men must agree to practice adequate contraception&#xD;
             (barrier or hormone methods or intra uterine device (IUD) for women and a condom for&#xD;
             men) throughout the study treatment and for at least up to day 51 (for female) and day&#xD;
             111 (for male) of the trial (i.e. 30 (for female) and 90 (for male) days after the&#xD;
             last dose of the IMP)&#xD;
&#xD;
          5. Female subjects of childbearing potential must have a negative urine or serum&#xD;
             pregnancy test within 24 hours prior to study vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of neurological symptoms or signs, or anaphylactic shock following&#xD;
             administration of any vaccine.&#xD;
&#xD;
          2. Known or suspected (or have a high risk of developing) impairment/alteration of immune&#xD;
             function (excluding that normally associated with advanced age).&#xD;
&#xD;
          3. Receipt of: a) Immunosuppressive drugs: i) systemic glucocorticoids &gt;/= 10 mg&#xD;
             prednisone per day ii) cytotoxic drugs b) Investigational drugs within 30 days before,&#xD;
             or planned during, the study c) Blood products within 3 months before, or planned&#xD;
             during, the study d) Influenza vaccine within 6 months before the study) Other&#xD;
             vaccines within 30 days before, or planned during, the study&#xD;
&#xD;
          4. Any serious disease such as: cancer, autoimmune disease, advanced arteriosclerotic&#xD;
             disease or complicated diabetes mellitus, chronic obstructive pulmonary disease (COPD)&#xD;
             that requires oxygen therapy, acute or progressive hepatic disease, acute or&#xD;
             progressive renal disease, or congestive heart failure, as judged by the PI.&#xD;
&#xD;
          5. An acute illness, including an axillary temperature greater than 38 Celsius (38ºC),&#xD;
             occurred within 1 week before first vaccination&#xD;
&#xD;
          6. Positive positive urine pregnancy test prior to vaccination or women who are&#xD;
             breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamar Ben-Yedidia, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BiondVax Pharmaceuticals ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jagiellońskie Centrum Innowacji Sp.z o.o.</name>
      <address>
        <city>Kraków</city>
        <state>Ul. Bobrzyńskiego 14,</state>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jagiellońskie Centrum Innowacji Sp.z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>30348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>August 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2021</results_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>vaccine</keyword>
  <keyword>universal</keyword>
  <keyword>M-001</keyword>
  <keyword>Multimeric-001</keyword>
  <keyword>Flu</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03450915/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT03450915/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>M-001</title>
          <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
        </group>
        <group group_id="P2">
          <title>Saline</title>
          <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6230"/>
                <participants group_id="P2" count="6230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5827"/>
                <participants group_id="P2" count="5855"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="375"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population is the Intention-to-treat population, i.e. subjects who received at least one vaccination</population>
      <group_list>
        <group group_id="B1">
          <title>M-001</title>
          <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
        </group>
        <group group_id="B2">
          <title>Saline</title>
          <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6229"/>
            <count group_id="B2" value="6229"/>
            <count group_id="B3" value="12458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3082"/>
                    <measurement group_id="B2" value="3081"/>
                    <measurement group_id="B3" value="6163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3147"/>
                    <measurement group_id="B2" value="3148"/>
                    <measurement group_id="B3" value="6295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="8.7"/>
                    <measurement group_id="B2" value="64.6" spread="8.7"/>
                    <measurement group_id="B3" value="64.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3454"/>
                    <measurement group_id="B2" value="3486"/>
                    <measurement group_id="B3" value="6940"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2775"/>
                    <measurement group_id="B2" value="2743"/>
                    <measurement group_id="B3" value="5518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6227"/>
                    <measurement group_id="B2" value="6228"/>
                    <measurement group_id="B3" value="12455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1751"/>
                    <measurement group_id="B2" value="1749"/>
                    <measurement group_id="B3" value="3500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Croatia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2740"/>
                    <measurement group_id="B2" value="2736"/>
                    <measurement group_id="B3" value="5476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="947"/>
                    <measurement group_id="B2" value="949"/>
                    <measurement group_id="B3" value="1896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With qRT-PCR or Culture-confirmed Influenza-like Illness</title>
        <description>Prevention of influenza disease by comparing the occurrence of either qRT-PCR or culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.</description>
        <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
        <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>M-001</title>
            <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With qRT-PCR or Culture-confirmed Influenza-like Illness</title>
          <description>Prevention of influenza disease by comparing the occurrence of either qRT-PCR or culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.</description>
          <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5864"/>
                <count group_id="O2" value="5905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Both seasons</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5864"/>
                    <count group_id="O2" value="5905"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Season 2018/2019</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1906"/>
                    <count group_id="O2" value="1917"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Season 2019/2020</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3958"/>
                    <count group_id="O2" value="3988"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Events, New Onset Chronic Illness, and Non-solicited Adverse Events</title>
        <description>Number of participants with one or more Serious Adverse Events, New Onset Chronic illness, and Non-solicited Adverse Events assessed during one flu season per participant</description>
        <time_frame>From Day 0 to end of study completion by participant which coincides with end of flu season in the respective year, an average of 4 months per participant per year</time_frame>
        <population>Safety population comprises all subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>M-001</title>
            <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Events, New Onset Chronic Illness, and Non-solicited Adverse Events</title>
          <description>Number of participants with one or more Serious Adverse Events, New Onset Chronic illness, and Non-solicited Adverse Events assessed during one flu season per participant</description>
          <population>Safety population comprises all subjects enrolled</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6230"/>
                <count group_id="O2" value="6230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Onset Chronic Illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-solicited Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="781"/>
                    <measurement group_id="O2" value="760"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Culture-confirmed Influenza Incidence</title>
        <description>Occurrence of culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.</description>
        <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
        <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>M-001</title>
            <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Culture-confirmed Influenza Incidence</title>
          <description>Occurrence of culture confirmed influenza in the M-001 experimental group vs. placebo caused by any influenza A or B virus in association with a protocol defined Influenza Like Illness.</description>
          <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5864"/>
                <count group_id="O2" value="5905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Reduction of Severity of qRT-PCR or Culture-confirmed Influenza</title>
        <description>Assessed by reduction of severity of either qRT-PCR or culture-confirmed influenza illness by the reduction due to M-001 in the average number of days with respiratory or systemic symptoms during the first laboratory-confirmed influenza illness episode.</description>
        <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
        <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>M-001</title>
            <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction of Severity of qRT-PCR or Culture-confirmed Influenza</title>
          <description>Assessed by reduction of severity of either qRT-PCR or culture-confirmed influenza illness by the reduction due to M-001 in the average number of days with respiratory or systemic symptoms during the first laboratory-confirmed influenza illness episode.</description>
          <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5864"/>
                <count group_id="O2" value="5905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 7 - 14 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=14 - 21 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 21 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Influenza-like Illness Symptoms</title>
        <description>Assessment of number of participants having ILI symptoms in the experimental or control group</description>
        <time_frame>From Day 14 post-second vaccination day to end of influenza season, an average of 4 months per participant per year</time_frame>
        <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>M-001</title>
            <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
          </group>
          <group group_id="O2">
            <title>Saline</title>
            <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Influenza-like Illness Symptoms</title>
          <description>Assessment of number of participants having ILI symptoms in the experimental or control group</description>
          <population>Per protocol population comprises all subjects who received both doses of vaccine or placebo and had at least one contact with study staff after 15 days or more upon second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5864"/>
                <count group_id="O2" value="5905"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1231"/>
                    <measurement group_id="O2" value="1266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>M-001</title>
          <description>Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.&#xD;
M-001: A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.</description>
        </group>
        <group group_id="E2">
          <title>Saline</title>
          <description>Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.&#xD;
Saline: 0.9% sodium chloride (NaCl)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="6230"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="6230"/>
                <counts group_id="E2" subjects_affected="177" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction 6 (</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6230"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiac Valve Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiovascular Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiovascular Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>V</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis Subacute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Posterior Capsule Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pancreatitis Necrotising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse Event</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Facial Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Acute Hepatic Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Biliary Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute 0 0</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6230"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Corona Virus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bacterial Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pubis Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Fractured Coccyx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Meniscus Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Polymyalgia Rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Spinal Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Laryngeal Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Myelofibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Uterine Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma Of Colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Rectosigmoid Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Renal Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Small Cell Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Tongue Neoplasm Benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Adrenal Adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Breast Cancer Recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Breast Cancer Stage II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Dysplastic Naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cerebrospinal Fluid Circulation Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Ulnar Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Reactive Psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cystitis Noninfective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Endometrial Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Reproductive Tract Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="6230"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6230"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Chronic Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Steal Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bleeding Varicose Vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Vascular Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.1</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="781" subjects_at_risk="6230"/>
                <counts group_id="E2" subjects_affected="760" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6230"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6230"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="6230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6230"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="40" subjects_affected="38" subjects_at_risk="6230"/>
                <counts group_id="E2" events="37" subjects_affected="33" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="6230"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="6230"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="6230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="6230"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6230"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="6230"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="6230"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6230"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6230"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6230"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6230"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6230"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="77" subjects_at_risk="6230"/>
                <counts group_id="E2" events="60" subjects_affected="54" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="6230"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6230"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="113" subjects_affected="106" subjects_at_risk="6230"/>
                <counts group_id="E2" events="99" subjects_affected="90" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="6230"/>
                <counts group_id="E2" events="21" subjects_affected="19" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6230"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="60" subjects_affected="57" subjects_at_risk="6230"/>
                <counts group_id="E2" events="65" subjects_affected="60" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="50" subjects_affected="42" subjects_at_risk="6230"/>
                <counts group_id="E2" events="57" subjects_affected="55" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="43" subjects_affected="40" subjects_at_risk="6230"/>
                <counts group_id="E2" events="43" subjects_affected="41" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="35" subjects_affected="33" subjects_at_risk="6230"/>
                <counts group_id="E2" events="42" subjects_affected="39" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="6230"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="6230"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="6230"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="28" subjects_affected="26" subjects_at_risk="6230"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="6230"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6230"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="6230"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="6230"/>
              </event>
              <event>
                <sub_title>Hypertensive Crises</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Scientific Officer &amp; Clinical Management</name_or_title>
      <organization>BiondVax Pharmaceuticals ltd.</organization>
      <phone>+97289302529 ext 5103</phone>
      <email>benyedidia@BiondVax.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

